We will continue to monitor tumor markers during follow-up, specifically carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA 19-9) serum levels, due to the risk of developing a metachronous biliary malignancy [6]. This evidence concerns the gene CEACAM5 and cancer.